{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:27:55Z","timestamp":1790422075476,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:00:00Z","timestamp":1364342400000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to evaluate whether the T\u2010type calcium channel antagonist MK\u20108998 was effective in treating acute psychosis in patients with schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a randomized, double\u2010blind, parallel\u2010group study. After a placebo lead\u2010in, acutely psychotic inpatients with schizophrenia were randomized to 4\u2009weeks of MK\u20108998 12\/16\u2009mg daily (<jats:italic>N<\/jats:italic>\u2009=\u200986), olanzapine 10\/15\u2009mg daily (<jats:italic>N<\/jats:italic>\u2009=\u200947), or placebo (<jats:italic>N<\/jats:italic>\u2009=\u200983). The primary efficacy measure was score on the Positive and Negative Syndrome Scale (PANSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 216 randomized patients, 158 completed the 4\u2010week study: MK\u20108998\u2009=\u200958 (67.4%), olanzapine\u2009=\u200938 (80.9%), and placebo\u2009=\u200962 (74.7%). The mean changes from baseline in PANSS score at week 4 for MK\u20108998 and olanzapine were not significantly different from placebo: MK\u20108998\u2013placebo difference\u2009=\u2009\u22120.6 [95% confidence interval (CI): \u22127.0, 5.8],<jats:italic>p<\/jats:italic>\u2009=\u20090.9; olanzapine\u2013placebo difference\u2009=\u2009\u22124.3 [95% CI: \u221211.7, 3.1),<jats:italic>p<\/jats:italic>\u2009=\u20090.3. A responder rate analysis (\u226520% improvement from baseline in PANSS score) suggested an advantage of olanzapine over placebo (odds ratio\u2009=\u20092.20 [95% CI: 0.95, 5.09],<jats:italic>p<\/jats:italic>\u2009=\u20090.07) but no effect of MK\u20108998 over placebo (odds ratio\u2009=\u20091.28 [95% CI: 0.62, 2.64],<jats:italic>p<\/jats:italic>\u2009=\u20090.5). Treatments were generally well tolerated, but more patients reported adverse events for MK\u20108998 (47.7%) and olanzapine (48.9%) than placebo (37.3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MK\u20108998 was not effective in treating acutely psychotic inpatients with schizophrenia, as measured by PANSS score at week 4. Because of the limited efficacy of the active comparator, we cannot exclude the possibility that T\u2010type calcium channel antagonists could prove to be effective in schizophrenia. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2289","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T06:59:10Z","timestamp":1364367550000},"page":"124-133","source":"Crossref","is-referenced-by-count":35,"title":["Randomized controlled study of the T\u2010type calcium channel antagonist MK\u20108998 for the treatment of acute psychosis in patients with schizophrenia"],"prefix":"10.1002","volume":"28","author":[{"given":"Michael F.","family":"Egan","sequence":"first","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp. Whitehouse, Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp. Whitehouse, Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp. Whitehouse, Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Troyer","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp. Whitehouse, Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor N.","family":"Uebele","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp. Whitehouse, Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerii","family":"Pidkorytov","sequence":"additional","affiliation":[{"name":"Institute of Neurology, Psychiatry and Narcology AMS Kharkiv Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Cox","sequence":"additional","affiliation":[{"name":"Worldwide Clinical Trials Ojai CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Murphy","sequence":"additional","affiliation":[{"name":"Worldwide Clinical Trials King of Prussia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Snavely","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp. Whitehouse, Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lines","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp. Whitehouse, Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Michelson","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp. Whitehouse, Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103174013"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245617"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(95)00069-P"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.09.035"},{"issue":"5","key":"e_1_2_7_8_1","first-page":"10","article-title":"Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients","volume":"62","author":"Cutler NR","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","unstructured":"DugganL FentonM RathboneJ DardennesR El\u2010DosokyA IndranS.2005.Olanzapine for schizophrenia. Cochrane Database Syst. Rev. (2) CD001359.","DOI":"10.1002\/14651858.CD001359.pub2"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0026-895X(25)08923-0","article-title":"Preferential block of T\u2010type calcium channels by neuroleptics in neural crest\u2010derived rat and human C cell lines","volume":"42","author":"Enyeart JJ","year":"1992","journal-title":"Mol Pharmacol"},{"key":"e_1_2_7_11_1","unstructured":"GuyW.1976.EDCEU Assessment Manual for Psychopharmacology\u2014Revised. U.S. Department of Health Education and Welfare Public Health Service Alcohol Drug Abuse and Mental Health Administration NIMH Psychopharmacology Research Branch Division of Extramural Research Programs second ed. NIMH Rockville MD. pp. 218\u2013222. DHEW Publ. No. ADM 76\u2010338."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2008.11.003"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.31887\/DCNS.2010.12.3\/jkane","article-title":"Pharmacologic treatment of schizophrenia","volume":"12","author":"Kane JM","year":"2010","journal-title":"Dialogues Clin Neurosci"},{"key":"e_1_2_7_14_1","volume-title":"Positive and Negative Syndrome Scale Manual","author":"Kay SR","year":"1994"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn110"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.171058"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32832a16da"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"e_1_2_7_19_1","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre\u2013post designs","volume":"62","author":"Liang K","year":"2000","journal-title":"Sankhy\u0101: The Indian Journal of Statistics"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3639"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.15222"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519060-00003"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_7_25_1","first-page":"1172","article-title":"How to examine patients using the Abnormal Involuntary Movement Scale","volume":"39","author":"Munetz MR","year":"1988","journal-title":"Hosp. Community Psychiatry"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1632"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1523\/JNEUROSCI.22-02-00396.2002","article-title":"Differential inhibition of T\u2010type calcium channels by neuroleptics","volume":"22","author":"Santi CM","year":"2002","journal-title":"J Neurosci"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36954"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.11.015"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800830n"},{"key":"e_1_2_7_32_1","first-page":"20","article-title":"Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting","volume":"3","author":"Zhang Y","year":"2009","journal-title":"Fron.Neur. Circuits"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2289","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T02:16:22Z","timestamp":1745979382000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1002\/hup.2289"],"URL":"https:\/\/doi.org\/10.1002\/hup.2289","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}